Brian Olshansky, MD
Cardiovascular Disease · Iowa City, IANPI 1962483347
Payments from drug & device makers
Across 474 payments — averaging $461.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$110K
- Amarin Pharma, Inc.$27K
- Boehringer Ingelheim$22K
- Sanofi-aventis U.S. LLC$18K
- Abbott$9K
- Atricure, Inc.$8K
- plus $25K from 27 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 138 | $109,992 |
| Amarin Pharma, Inc. | 29 | $26,730 |
| Boehringer Ingelheim | 13 | $21,658 |
| Sanofi-aventis U.S. LLC | 8 | $18,416 |
| Abbott | 43 | $8,910 |
| Atricure, Inc. | 13 | $7,840 |
| ZOLL Respicardia, Inc. | 5 | $4,162 |
| Altathera Pharmaceuticals LLC | 5 | $4,016 |
| AstraZeneca | 3 | $3,514 |
| Boston Scientific | 49 | $3,332 |
| Biosense Webster, Inc. | 53 | $3,216 |
| Medtronic(2 entities) | 27 | $2,241 |
| Impulse Dynamics (USA) Inc. | 11 | $881 |
| Irhythm Technologies, Inc. | 4 | $734 |
| Infobionic, Inc | 5 | $450 |
| Artivion, Inc. | 1 | $400 |
| Johnson & Johnson | 13 | $359 |
| Cardiva Medical, Inc. | 2 | $224 |
| E.r. Squibb & Sons, L.L.C. | 6 | $223 |
| Boehringer Ingelheim International GmbH | 1 | $214 |
| Biotronik Inc. | 4 | $211 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $197 |
| Elutia, Inc. | 7 | $194 |
| Philips North America LLC | 4 | $169 |
| Aidoc Medical Ltd | 1 | $131 |
| Amgen | 7 | $102 |
| Novartis | 6 | $91 |
| CSL Behring | 1 | $80 |
| Pfizer | 4 | $56 |
| Esperion Therapeutics, Inc. | 2 | $36 |
| Novo Nordisk | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Cook Medical LLC | 1 | $12 |
How this compares
$218,829 in reported general payments places this provider in the 95th percentile of 142 cardiovascular disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Iowa City
- Jennifer RobinsonIowa City$1.3M
- Suvasini LakshmananIowa City$156K
- Kimberly StaffeyIowa City$7K
- Aaron SifuentesIowa City$5K
- Rakesh PonnapureddyIowa City$3K
- Corina IorgoveanuIowa City$2K
- Michael HajduIowa City$2K
- Boniface MalanguIowa City$2K
- Ferhaan AhmadIowa City$2K
- Brett JohnsonIowa City$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.